Companies · Healthtech

Shine Medical Technologies, Inc.

JANESVILLE · Healthtech · refined from filed group “Other Health Care

Diligence memoA one-page analyst read on Shine Medical Technologies, Inc. — recommendation, valuation, rhythm, risks.
$83.7M
Total raised · real
5
Rounds
1.0×
Latest step-up
Top 6%
Sector rank · raised
Series B
Latest stage · inferred · Fri Apr 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

Shine Medical Technologies, Inc. looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the healthtech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.00× the median modeled value of Series B Healthtech companies in 2019–2021 (56 peers) — value vs value, same stage and era.
  • Within the normal band (100% of peer median) for its niche.
Dormant
  • Last raise 7.2 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Healthtech

Shine Medical Technologies, Inc. is one of 2138 Healthtech companies tracked from JANESVILLE. By capital raised it ranks among the largest (ahead of 95% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
99
Investors (latest)
2019-04-26
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$250M$500M$750M$1.0BSeed · 2010-12-24 Raised $2.4M (real) Modeled valuation $68M (est)Seed2010Seed · 2010-12-24 Raised $1.4M (real) Modeled valuation $39M (est)Seed2010Series A · 2010-12-24 Raised $11M (real) Modeled valuation $258M (est)Series A2010Series A · 2010-12-24 Raised $5.4M (real) Modeled valuation $123M (est)Series A2010Series B · 2013-10-11 Raised $29M (real) Modeled valuation $727M (est)Series B2013Series A · 2013-10-11 Raised $12M (real) Modeled valuation $260M (est)Series A2013Series B · 2013-10-11 Raised $27M (real) Modeled valuation $674M (est)Series B2013Series B · 2017-08-25 Raised $6.9M (real) Modeled valuation $171M (est)Series B2017Series B · 2018-04-20 Raised $18M (real) Modeled valuation $445M (est)Series B2018Series B · 2019-04-26 Raised $18M (real) Modeled valuation $448M (est)Series B2019+$1.4M+$11M+$5.4M+$29M+$12M+$27M+$6.9M+$18M+$18MCumulative $132M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$2.4M · 2010
Seed extension$1.4M · 2010
Series A$11.4M · 2010
Series A extension$5.4M · 2010
Series B$29.3M · 2013
Bridge · Series B-stage$11.5M · 2013smaller follow-on
Series B extension$27.2M · 2013
Series B extension$6.9M · 2017
Series B extension$18.0M · 2018
Series B extension$18.1M · 2019

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 75%.

Modeled valuation trajectory
$448.1M
Base estimate est.
$42.5M
Conservative case
$1.7B
Upside case
$100.5M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ba $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the healthtech sector profile. Directional, not a quoted figure.

Seed · modeled $67.5M · 2010-12-242010Seed · modeled $38.7M · 2010-12-24Series A · modeled $258.2M · 2010-12-24Series A · modeled $122.7M · 2010-12-24Series B · modeled $727.3M · 2013-10-11Series A · modeled $260.4M · 2013-10-11Series B · modeled $673.6M · 2013-10-11Series B · modeled $170.6M · 2017-08-25Series B · modeled $445.1M · 2018-04-20Series B · modeled $448.1M · 2019-04-262019
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
64%
Survival probability
42% low · 78% high
1.38×/yr
Annual markup
1.67×/yr upside case
6.0 yr
Elapsed time used
7.2 yr actual, capped for stale marks
healthtech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
11 mo
Avg between rounds
$10.0M/yr
Capital velocity
15.5 yr
On record since
2010
First round
10
Rounds on file
How it compares to the market

Benchmarked against 2138 companies in Healthtech. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 19× above median
This company$83.7M
Sector median$4.5M
Latest round — vs other Series B rounds in sector (real $, this stage) 1.0× of median
This company$18.1M
Sector median$18.3M
Modeled value — vs sector median (estimate, all stages) 13× above median
This company$448.1M
Sector median$33.8M

Raised more than 95% of sector peers (real $). Modeled value above 93% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #28 of 56.

This companyCohort peer
$100.0M$1.0B$10.0M$100.0M$1.0BCapital raised (log)Solera Health, Inc. · Series B Raised $79.1M · modeled $935.6M (est)Icebreaker Health, Inc. · Series B Raised $51.5M · modeled $890.1M (est)Buoy Health, Inc. · Series B Raised $66.7M · modeled $837.4M (est)Stroma Medical Corp · Series B Raised $43.0M · modeled $767.6M (est)HealthJoy, Inc. · Series B Raised $45.5M · modeled $743.5M (est)Appriss Health Holdings, Inc. · Series B Raised $38.1M · modeled $718.0M (est)Superconductive Health, Inc. · Series B Raised $61.0M · modeled $717.0M (est)Wheel Health, Inc. · Series B Raised $36.7M · modeled $686.1M (est)Mindoula Health, Inc. · Series B Raised $30.7M · modeled $663.2M (est)Flowonix Medical Inc · Series B Raised $104.6M · modeled $656.8M (est)Sirona Medical, Inc. · Series B Raised $53.0M · modeled $638.3M (est)HealthPlan One Holdings, Inc. · Series B Raised $28.6M · modeled $621.6M (est)Shine Medical Technologies, Inc. (this company) Raised $83.7M · modeled $448.1M (est)Shine Medical Technologies, Inc.
CompanyStageRaised · realValue · estvs peer med.
Solera Health, Inc.Series B$79.1M$935.6M2.09×
Icebreaker Health, Inc.Series B$51.5M$890.1M1.99×
Buoy Health, Inc.Series B$66.7M$837.4M1.87×
Stroma Medical CorpSeries B$43.0M$767.6M1.72×
HealthJoy, Inc.Series B$45.5M$743.5M1.66×
Appriss Health Holdings, Inc.Series B$38.1M$718.0M1.61×
Superconductive Health, Inc.Series B$61.0M$717.0M1.60×
Wheel Health, Inc.Series B$36.7M$686.1M1.53×
Mindoula Health, Inc.Series B$30.7M$663.2M1.48×
Flowonix Medical IncSeries B$104.6M$656.8M1.47×
Sirona Medical, Inc.Series B$53.0M$638.3M1.43×
HealthPlan One Holdings, Inc.Series B$28.6M$621.6M1.39×
Shine Medical Technologies, Inc. this companySeries B$83.7M$448.1M1.00×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$2.4M2010-12-24$12.2M$67.5M85%
Seed$1.4M2010-12-24$7.0M$38.7M85%
Series A$11.4M2010-12-24$52.0M$258.2M85%
Series A$5.4M2010-12-24$24.7M$122.7M85%
Series B$29.3M2013-10-11$163.0M$727.3M90%
Series A$11.5M2013-10-11$52.4M$260.4M85%
Series B$27.2M2013-10-11$151.0M$673.6M90%
Series B$6.9M2017-08-25$38.2M$170.6M90%
Series B$18.0M2018-04-20$99.8M$445.1M90%
Series B$18.1M2019-04-26$100.5M$448.1M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$2.4M2010-12-24
    • First recorded raise — entered as Seed.
    • 13 investors on this round.
  2. Seed$1.4M2010-12-24
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.7× smaller than the prior — bridge or down round.
    • 12 investors on this round.
  3. Series A$11.4M2010-12-24
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 8.2× larger than the prior — scaling up.
    • 15 investors on this round.
  4. Series A$5.4M2010-12-24
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.1× smaller than the prior — bridge or down round.
    • 15 investors on this round.
  5. Series B$29.3M2013-10-11
    • Raised again after 34 mo — slower than the ~14 mo sector norm.
    • Round 5.4× larger than the prior — scaling up.
    • Switched to Rule 506(b) (was Rule 06).
    • 217 investors on this round.
  6. Series A$11.5M2013-10-11
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.5× smaller than the prior — bridge or down round.
    • 93 investors on this round.
  7. Series B$27.2M2013-10-11
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.4× larger than the prior — scaling up.
    • 208 investors on this round.
  8. Series B$6.9M2017-08-25
    • Raised again after 46 mo — slower than the ~14 mo sector norm.
    • Round 3.9× smaller than the prior — bridge or down round.
    • 26 investors on this round.
  9. Series B$18.0M2018-04-20
    • Came back fast: 8 mo vs the ~14 mo sector norm.
    • Round 2.6× larger than the prior — scaling up.
    • 122 investors on this round.
  10. Series B$18.1M2019-04-26
    • Raised 12 mo later, in step with the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 99 investors on this round.
Intelligence
2020 ~Q1
Modeled next raise · ~11mo cadence
$18.2M
Modeled next size est.range $18.1M$29.1M
1.0×
Last step-up
$10.0M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Gregory M. Smith3 other2017-08
Thomas Rockwell Mackie3 other2010-12
Philip M. Halpern2 other2013-10
Brad M. Wucherpfennig1 other2018-04
Gordon M. Gunnlaugsson1 other2018-04
Gregory Richard Piefer1 other2010-12
Anton M. Asmuth2013-10
Christopher H. Manuele2010-12
Darin Richard Janecek2013-10
David A. Weissburg2010-12
Donald H. Whelley2010-12
Donald M. Whelley2013-10
Fred H. Mancheski2010-12
Harsh M. Singh2019-04
James M. Costedio2013-10
Katrina M. Pitas2013-10
Richard Clermont Vann Bynum2010-12
Richard H. Leazer2010-12
Richard Richard Vann Bynum2013-10
Richard Vann Bynum2010-12
Stephen Clermont Hathaway2010-12
Steve M. Miltenberger2018-04
Todd M. Asmuth2013-10
Registry & provenance

Shine Medical Technologies, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1514300
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Illuminated Holdings, Inc.OtherSeries D+$523.7M$1.4Bnetwork6 shared operators
Monteris Medical US, Inc.HealthtechSeries B$82.5M$168.2Msame sector · same stage
Boulder Care, Inc.HealthtechSeries B$81.2M$249.8Msame sector · same stage
Okami Medical, Inc.HealthtechSeries B$77.2M$125.6Msame sector · same stage
Patient Home Monitoring Corp.HealthtechSeries B$72.5M$116.9Msame sector · same stage
Priority Private Care Management, Inc.HealthtechSeries B$70.2M$177.8Msame sector · same stage
Francis Medical, Inc.HealthtechSeries B$70.1M$234.0Msame sector · same stage
Commons Clinic Inc.HealthtechSeries B$69.8M$145.0Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Orient Health Inc.HealthtechSeries A$48.3M84%
Thrive Health Tech, Inc.HealthtechSeries A$16.5M84%
WELL Health Technologies Corp.HealthtechSeed$92.8M84%
HealthClicks, Inc.HealthtechSeed$46.3M83%
Healthjump Inc.HealthtechSeed$32.2M83%
Sheer Health, Inc.HealthtechSeed$32.6M83%
Fuse Medical, Inc.HealthtechSeed$90.8M83%
Health Intelligence Co LlcHealthtechSeries C$1.1B83%
Frequently asked
How much funding has Shine Medical Technologies, Inc. raised?
Shine Medical Technologies, Inc. has raised approximately $83.7M in disclosed capital across 5 recorded financing rounds, aggregated from public filings.
What is Shine Medical Technologies, Inc.'s estimated valuation?
Provath's modeled valuation for Shine Medical Technologies, Inc. is approximately $448.1M (modeled range $42.5M–$1.7B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Shine Medical Technologies, Inc. at?
Shine Medical Technologies, Inc.'s latest modeled financing stage is Series B. Its most recent recorded round closed around Fri Apr 26.
What does Shine Medical Technologies, Inc. do and where is it based?
Shine Medical Technologies, Inc. operates in the Healthtech sector, based in JANESVILLE.
Explore related

See where Shine Medical Technologies, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Shine Medical Technologies, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.